Chronic Heart Failure		ACCLAIM Phase III trial results presented Confirmatory ACCLAIM-II study planned for purposes of U.S. regulatory approval E.U. commercialization activities ongoing		More than 12 million people in North America and Europe have chronic heart failure and an estimated 4.4 million of these have NYHA Class II symptomatic impairment. Each year, in the U.S. alone, 300,000 deaths are associated with heart failure and annual healthcare costs are estimated to exceed $30 billion.
			Neuro-Inflammatory Conditions		Phase I trial completed		Neuro-inflammatory conditions including Alzheimer's disease, Parkinson's disease, and ALS (Lou Gehrig's disease), are estimated to affect more than 5 million people in North America, with the total cost of care estimated to exceed $75 billion annually.